Lexaria Bioscience Corp (LEXX)

Mar 03, 2025

Lexaria Bioscience stock hits 52-week low at $1.37 By Investing.com - Investing.com South Africa

Mar 03, 2025

Feb 27, 2025

Lexaria Bioscience Advances Strategy in GLP-1 Drug Sector - TipRanks

Feb 27, 2025

Feb 27, 2025

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience - TradingView

Feb 27, 2025

Feb 27, 2025

Could This Small Biotech Solve GLP-1 Drugs' Biggest Problems? Lexaria's Triple Strategy Explained - StockTitan

Feb 27, 2025

Feb 24, 2025

Lexaria Bioscience Advances GLP-1 Study with New Ethics Approval - TipRanks

Feb 24, 2025

Feb 24, 2025

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm - TradingView

Feb 24, 2025

Feb 24, 2025

Can This Small Biotech Transform GLP-1 Drugs From Shots to Pills? Clinical Trial Update - StockTitan

Feb 24, 2025

Feb 20, 2025

Lexaria Bioscience Targets Breakthrough in Oral Diabetes Medication - TipRanks

Feb 20, 2025

Feb 20, 2025

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide - WICZ

Feb 20, 2025

Feb 20, 2025

Can This Small Biotech Revolutionize $30B GLP-1 Market With First-Ever Oral Liraglutide? - StockTitan

Feb 20, 2025

Feb 17, 2025

Lexaria Bioscience Corp. (NASDAQ:LEXX) Sees Significant Decline in Short Interest - Defense World

Feb 17, 2025

Feb 14, 2025

Lexaria Bioscience stock hits 52-week low at $1.62 - MSN

Feb 14, 2025

Feb 13, 2025

Lexaria Secures Two New Patents for Epilepsy Treatment with DehydraTECH - MSN

Feb 13, 2025

Feb 12, 2025

Lexaria secures new patents for epilepsy treatment tech By Investing.com - Investing.com Nigeria

Feb 12, 2025

Feb 11, 2025

Lexaria Bioscience stock hits 52-week low at $1.62 By Investing.com - Investing.com South Africa

Feb 11, 2025

Feb 11, 2025

Lexaria secures new patents for epilepsy treatment tech - MSN

Feb 11, 2025

Feb 11, 2025

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy - WICZ

Feb 11, 2025

Feb 11, 2025

Lexaria's Game-Changing Epilepsy Patents Outperform Epidiolex Technology | LEXX - StockTitan

Feb 11, 2025

Feb 06, 2025

Lexaria Initiates Groundbreaking Biodistribution Study for DehydraTECH GLP-1 - TipRanks

Feb 06, 2025

Feb 06, 2025

Revolutionary GLP-1 Study: Lexaria's DehydraTECH Goes Head-to-Head with Rybelsus - StockTitan

Feb 06, 2025

Feb 05, 2025

Lexaria Advances Human Study on Diabetes and Weight Loss Treatment - TipRanks

Feb 05, 2025

Feb 05, 2025

Revolutionary GLP-1 Breakthrough: Lexaria's Technology Matches Zepbound Efficacy with Fewer Side Effects - StockTitan

Feb 05, 2025

Jan 31, 2025

Lexaria reports promising drug delivery study results - Investing.com India

Jan 31, 2025

Jan 31, 2025

Research Analysts Issue Forecasts for LEXX Q2 Earnings - Defense World

Jan 31, 2025

Jan 30, 2025

Lexaria Bioscience Strengthens GLP-1 Drug Delivery Focus and Expands Patent Portfolio in 2024 - TipRanks

Jan 30, 2025

Jan 30, 2025

Lexaria Releases Annual Letter from the CEO - WICZ

Jan 30, 2025

Jan 30, 2025

GLP-1 Game-Changer: This Small Biotech Found How to Slash Semaglutide Side Effects by 60% - StockTitan

Jan 30, 2025

Jan 30, 2025

What is Zacks Small Cap’s Estimate for LEXX Q4 Earnings? - Defense World

Jan 30, 2025

Jan 28, 2025

LEXX: IRB Approval Clears Way for GLP-1 Study #5 - Yahoo Finance

Jan 28, 2025

Jan 26, 2025

HC Wainwright Has Lowered Expectations for Lexaria Bioscience (NASDAQ:LEXX) Stock Price - Defense World

Jan 26, 2025

Jan 24, 2025

Lexaria Bioscience stock target cut to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa

Jan 24, 2025

Jan 24, 2025

Lexaria Bioscience stock target cut to $7 at H.C. Wainwright - Investing.com

Jan 24, 2025

Jan 17, 2025

Lexaria Bioscience Holds Successful Shareholder Meeting; Votes in New Directors and Approves Proposals - Defense World

Jan 17, 2025

Jan 15, 2025

Lexaria Bioscience shareholders approve board and auditor selections - Investing.com

Jan 15, 2025

Jan 15, 2025

Lexaria Bioscience Advances with Human Study for Oral Liraglutide - TipRanks

Jan 15, 2025

Jan 15, 2025

LEXXLexaria Bioscience Corp. Latest Stock News & Market Updates - StockTitan

Jan 15, 2025

Jan 15, 2025

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval - WICZ

Jan 15, 2025

Jan 15, 2025

Lexaria Gets Green Light for Oral Weight Loss Drug Trial, Aims to Replace Saxenda Injections - StockTitan

Jan 15, 2025

Jan 14, 2025

Lexaria’s Oral Drug Shows Promising Results Against Eli Lilly’s Injection - TipRanks

Jan 14, 2025

Jan 14, 2025

Lexaria's Oral GLP-1 Drug Shows 47% Fewer Side Effects Than Injectable Zepbound in Clinical Study - StockTitan

Jan 14, 2025

Jan 14, 2025

Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Jan 14, 2025

Jan 13, 2025

Geode Capital Management LLC Increases Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World

Jan 13, 2025

Jan 10, 2025

Lexaria Bioscience Corp. Reports Earnings Results for the First Quarter Ended November 30, 2024 - Marketscreener.com

Jan 10, 2025

Jan 10, 2025

Lexaria Bioscience Earnings Analysis: Q1 Recap - Benzinga

Jan 10, 2025

Jan 10, 2025

Lexaria Bioscience Corp. (LEXX) reports earnings - Quartz

Jan 10, 2025

Jan 06, 2025

NRx Pharmaceuticals (NASDAQ:NRXP) and Lexaria Bioscience (NASDAQ:LEXX) Head to Head Contrast - Defense World

Jan 06, 2025

Jan 05, 2025

Lexaria Bioscience Announces Executive Management Agreement ChangesLexaria Bioscience Corp. (OTCMKTS:LXRP) recently disclosed key alterations to its Executive Management Agreement in a current report filed with the Securities and Exchange Com - Defense World

Jan 05, 2025